埃勒布西兰和PEG-IFNα治疗慢性乙型肝炎感染:一个部分随机的,开放的,第二阶段试验
Grace Lai-Hung Wong1, Man-Fung Yuen2, Bingliang Lin3
1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
Nature medicine
|November 7, 2025
概括
埃尔布西兰和基化干扰素α (PEG-IFNα) 的组合显著改善了慢性乙型肝炎病毒 (HBV) 感染中的乙型肝炎表面抗原 (HBsAg) 损失率. 治疗性疫苗BRII-179可能有助于识别可能对治疗有反应的患者.
科学领域:
- 肝病学和病毒免疫学
- 抗RNA干扰治疗药物 抗RNA干扰治疗
- 疫苗开发 疫苗开发
背景情况:
- 实现慢性乙型肝炎病毒 (HBV) 感染的功能治疗仍然是当前治疗的挑战.
- 目前的疗法很少导致持续的病毒清除或功能治愈.
- 正在探索结合小干扰RNA (siRNA) 和免疫调节剂的新型治疗策略.
研究的目的:
- 为了评估elebsiran的疗效,一个siRNA,与基化干扰素α (PEG-IFNα) 结合用于慢性HBV治疗.
- 为了比较组合治疗与PEG-IFNα单一治疗.
- 评估治疗疫苗BRII-179在识别免疫反应良好的患者和增强乙型肝炎表面抗原 (HBsAg) 损失率方面的作用.
主要方法:
- 一项随机研究涉及慢性HBV感染的病毒抑制参与者.
- 第一部分:参与者单独接受PEG-IFNα或与两种不同剂量的elebsiran结合.
- 第二部分:之前接受过elebsiran和BRII-179治疗的参与者根据抗HBs水平进行了分类,并接受了组合治疗.
主要成果:
- 与elebsiran和PEG-IFNα的联合治疗导致比PEG-IFNα单一治疗更高的HBsAg损失率.
- 具体来说,治疗后24周的HBsAg损失率为21.1% (elebsiran 200mg + PEG-IFNα),33.3% (elebsiran 100mg + PEG-IFNα) 和5.6% (仅使用PEG-IFNα).
- 在第二部分中,与非响应者 (8.3%) 相比,BRII-179抗HBs响应者 (42.1%) 的HBsAg损失更高,这表明BRII-179在患者选择中发挥了作用.
结论:
- 埃勒布西兰和PEG-IFNα的组合表明,在慢性HBV中实现持续的HBsAg损失方面具有添加性益处.
- 埃勒布西兰和PEG-IFNα联合治疗是安全的,并且耐受良好.
- BRII-179可能成为免疫分析的宝贵工具,以优化HBV患者的治愈结果.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...


